Jul. 1 at 5:39 PM
$CGTX big pharma is sitting on a lot of cash and impending patent cliffs. A lot of what management has done here is in preparation of negotiations (patent, conferences, AMD discussions)
We won't know the outcome until due diligence. I am very confident we will get something promising to allow the company to either handoff the work, or secure funding into the START readout, and then secure a bigger payout.
Will be great to have a path forward against this disease.
